Literature DB >> 22424191

Idiopathic inflammatory myopathies.

Melinda Vincze1, Katalin Danko.   

Abstract

Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete. Our increasing knowledge about the risk factors, genetic susceptibility and immunological pathways in the disease mechanism leads to the establishment of a new, immunogenetically and serologically validated diagnostic criteria system. The treatment of idiopathic inflammatory myopathy is also a complex task requiring much experience. The aims of therapy are to increase muscle strength, prevent the development of contractures and manage the systemic manifestations of the disease. The most important one is the early detection of diseases and patients' immunological control in special centres. Using the basis therapeutic drugs temporary or permanent remission can be achieved, which improves patientsG' quality of life and functional ability. Rehabilitation and physiotherapy in the remission period may significantly improve the outcome of patients with functional disorders. The introduction of new biological therapies further allows us to control the myositis patients' state more effectively. The aim of this review is to summarise our knowledge about clinical symptoms, pathomechanism, as well as genetic, serologic and environmental risk factors. We would also like to present the way to diagnosis and the latest research about diagnostic criteria system, proposed outcome measures and therapeutic possibilities.
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22424191     DOI: 10.1016/j.berh.2012.01.013

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  9 in total

Review 1.  The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Bernadette C Tobler-Ammann; Britta Maurer; Ruud H Knols
Journal:  Rheumatol Int       Date:  2015-08-14       Impact factor: 2.631

2.  RET promoter variations in familial African degenerative leiomyopathy (ADL): first report of a possible genetic-environmental interaction.

Authors:  C Van Rensburg; S W Moore; M Zaahl
Journal:  Pediatr Surg Int       Date:  2012-10-07       Impact factor: 1.827

Review 3.  Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.

Authors:  Kirsty McLellan; Charalampia Papadopoulou
Journal:  Curr Rheumatol Rep       Date:  2022-06-10       Impact factor: 4.686

4.  HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases.

Authors:  Karolina Cseri; János Vincze; Julianna Cseri; János Fodor; Zoltán Csernátony; László Csernoch; Katalin Dankó
Journal:  J Muscle Res Cell Motil       Date:  2015-03-12       Impact factor: 2.698

5.  Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.

Authors:  Marisa Fernandes das Neves; Joana Caetano; Susana Oliveira; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-08-03

6.  [New aspects on the pathogenesis of myositis].

Authors:  B Stuhlmüller; E Feist; T Häupl; G-R Burmester; N Pipitone
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

7.  HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.

Authors:  Xiaoming Shu; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

8.  Reliability and validity of the German version of the Myositis Activities Profile (MAP) in patients with inflammatory myopathy.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Caroline H G Bastiaenen; Britta Maurer; Ruud H Knols
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

9.  Effect of butylphthalide intervention on experimental autoimmune myositis in guinea pigs.

Authors:  Juan Chen; Jingyang Wang; Jiyan Zhang; Chuanqiang Pu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.